Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sanofi, NIID Sign MOU on Infectious Disease Collaboration
October 15, 2025
- Astellas’ Vyloy Combo Fails to Improve Survival in PII Pancreatic Cancer Study
October 15, 2025
- Mitsubishi Tanabe Files Uplizna Label Expansion for gMG in Japan
October 15, 2025
- Novo, Sumitomo Extend Co-Promotion Partnership to Wegovy
October 15, 2025
- Kite Looks to Expand Japan CAR-T Footprint, Boosts Supply Infrastructure
October 15, 2025
- Moderna Launches LP.8.1-Adapted Spikevax for Ages 6 Months to 11 Years
October 15, 2025
- Chugai to Develop Roche’s GLP-1/GIP Agent CT-388 in Japan
October 14, 2025
- JT, Torii File Tapinarof Cream for Pediatric Atopic Dermatitis in Japan
October 14, 2025
- Eisai Maps Out 3-Pronged Strategy to Promote Leqembi: COO Naito
October 10, 2025
- NANO MRNA to Launch Investment Arm, Set Up Fund with SBI to Acquire Unlisted Biotechs
October 10, 2025
- Japan’s Medical and Pharma DX Market to Reach 1.35 Trillion Yen in 2035: Fuji Keizai
October 10, 2025
- Nichi-Iko to Offload AGs of Allegra and Plavix to Meiji Group
October 8, 2025
- NHI-Market Price Gap Likely to Narrow Further in 2025; Will It Drop into 4% Zone?
October 8, 2025
- Kissei Grants Linzagolix Rights to Searchlight in Canada
October 8, 2025
- Enhertu Combo Filed for First-Line HER2 Breast Cancer in Japan
October 8, 2025
- Leqembi Iqlik Autoinjector Now Available in US: Eisai/Biogen
October 8, 2025
- Japan Ethical Drug Sales Edge Up 0.4% in August: Crecon
October 8, 2025
- Pharma Industry Generally Welcomes New LDP Leader Takaichi
October 7, 2025
- Boehringer Ingelheim Taps Marc Hasson to Lead Japan Operations
October 7, 2025
- Chugai CEO Lauds Sakaguchi’s Nobel-Winning Work
October 7, 2025
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…